Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $8.1 million.

  • RxSight's Share-based Compensation rose 2374.85% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year increase of 4269.91%. This contributed to the annual value of $24.6 million for FY2024, which is 5645.24% up from last year.
  • Per RxSight's latest filing, its Share-based Compensation stood at $8.1 million for Q3 2025, which was up 2374.85% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, RxSight's Share-based Compensation registered a high of $8.5 million during Q2 2025, and its lowest value of $1.2 million during Q1 2021.
  • Over the past 5 years, RxSight's median Share-based Compensation value was $4.0 million (recorded in 2023), while the average stood at $4.4 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 13581.24% in 2021, then skyrocketed by 154.27% in 2022.
  • Over the past 5 years, RxSight's Share-based Compensation (Quarter) stood at $2.9 million in 2021, then rose by 1.54% to $3.0 million in 2022, then soared by 49.39% to $4.4 million in 2023, then skyrocketed by 64.56% to $7.3 million in 2024, then rose by 11.34% to $8.1 million in 2025.
  • Its Share-based Compensation was $8.1 million in Q3 2025, compared to $8.5 million in Q2 2025 and $7.1 million in Q1 2025.